NCT05227521

Brief Summary

In a recent cross-sectional study, it was shown that people with a good observed upper limb (UL) motor function but low perceived UL activity show a reduced daily-life UL activity. The investigators will now investigate the feasibility of a phone-monitored home exercise and feedback program for the UL following stroke and the preliminary effects on the perceived UL activity and actual daily-life UL activity for participants with good observed UL motor function but low perceived UL activity in the chronic phase post-stroke.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
19

participants targeted

Target at P25-P50 for phase_1 stroke

Timeline
Completed

Started Jan 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 14, 2022

Completed
17 days until next milestone

Study Start

First participant enrolled

January 31, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 7, 2022

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 25, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 25, 2023

Completed
Last Updated

July 3, 2023

Status Verified

June 1, 2023

Enrollment Period

1.4 years

First QC Date

January 14, 2022

Last Update Submit

June 30, 2023

Conditions

Keywords

upper limbdaily life activityhome-based exercise programfeedbackperceived activity

Outcome Measures

Primary Outcomes (10)

  • Recruitment rate

    % of individuals who were eligible and agreed to participate

    45 days (post-intervention)

  • Retention rate

    % of participants who completed the intervention

    45 days (post-intervention)

  • Adherence to the intervention protocol

    % of participants who achieved 12 hours of average weekly exercise

    45 days (post-intervention)

  • Safety

    \# of participants with increased pain while performing exercises as measured by visual analogue scale

    45 days (post-intervention)

  • Activity ratio

    Contribution to the activity of one upper limb (UL) versus the other: hours of activity of the affected divided by the unaffected UL

    Day 1 (enrolment)

  • Activity ratio

    Contribution to the activity of one upper limb (UL) versus the other: hours of activity of the affected divided by the unaffected UL

    Day 17 (baseline)

  • Activity ratio

    Contribution to the activity of one upper limb (UL) versus the other: hours of activity of the affected divided by the unaffected UL

    45 days (post-intervention)

  • Hand subscale of the Stroke Impact Scale version 3.0 (SIS-Hand)

    Perceived activity of the affected UL. Minimum 0 - maximum 100; higher scores mean better outcome.

    Day 1 (enrolment)

  • Hand subscale of the Stroke Impact Scale version 3.0 (SIS-Hand)

    Perceived activity of the affected UL. Minimum 0 - maximum 100; higher scores mean better outcome.

    Day 17 (baseline)

  • Hand subscale of the Stroke Impact Scale version 3.0 (SIS-Hand)

    Perceived activity of the affected UL. Minimum 0 - maximum 100; higher scores mean better outcome.

    45 days (post-intervention)

Secondary Outcomes (14)

  • Fugl-Meyer motor assessment - upper extremity (FMA-UE)

    Day 1 (enrolment), day 17 (baseline), 45 days (post-intervention)

  • Action Research Arm Test (ARAT)

    Day 17 (baseline), 45 days (post-intervention)

  • Motor Activity Log - 14 Item Version Amount Of Use (MAL-14 AOU)

    Day 17 (baseline), 45 days (post-intervention)

  • Motor Activity Log - 14 Item Version Quality Of Movement (MAL-14 QOM)

    Day 17 (baseline), 45 days (post-intervention)

  • Erasmus modified Nottingham Sensory Assessment (Em-NSA)

    Day 17 (baseline), 45 days (post-intervention)

  • +9 more secondary outcomes

Other Outcomes (7)

  • Demographics

    Day 1 (enrolment)

  • Stroke event data

    Day 1 (enrolment)

  • National Institutes of Health Stroke Scale (NIHSS)

    Day 1 (enrolment)

  • +4 more other outcomes

Study Arms (1)

AH-GRASP feedback intervention group

EXPERIMENTAL

All study participants will receive the AH-GRASP feedback intervention.

Behavioral: Adapted H-GRASP feedback program

Interventions

Combination of the Home-Graded Repetitive Arm Supplementary Program with in home accelerometer-based feedback

AH-GRASP feedback intervention group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Voluntary written informed consent of the participant has been obtained prior to any screening procedures
  • First-ever unilateral, supratentorial stroke, as defined by the American Heart Association/American Stroke Association
  • Minimum six months after stroke
  • Living in the community
  • ≥18 years old
  • Good observed UL motor function but low perceived UL activity. Good observed UL motor function is defined as a score \>50/66 on the Fugl-Meyer Assessment-Upper Extremity (FMA-UE). Low perceived UL activity is defined as a score ≤75/100 on the hand subscale of the Stroke Impact Scale version 3.0 (SIS-Hand).

You may not qualify if:

  • Other neurological condition than stroke
  • Musculoskeletal disorder that affects UL use
  • No informed consent
  • Participation in an interventional Study with an investigational medicinal product (IMP) or device

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Private physiotherapy practices

Leuven, 3000, Belgium

Location

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Geert Verheyden, Professor

    KU Leuven

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 14, 2022

First Posted

February 7, 2022

Study Start

January 31, 2022

Primary Completion

June 25, 2023

Study Completion

June 25, 2023

Last Updated

July 3, 2023

Record last verified: 2023-06

Data Sharing

IPD Sharing
Will not share

Locations